Publications 2022

Bersuder, E., Terciolo, C., Lechevrel, M., Martin, E., Quesnelle, C., Freund, J.-N., Reimund, J.-M., & Gross, I. (2022). Mesalazine initiates an anti-oncogenic β-catenin / MUCDHL negative feed-back loop in colon cancer cells by cell-specific mechanisms. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 146, 112543.
Delhorme, J.-B., Bersuder, E., Terciolo, C., Vlami, O., Chenard, M.-P., Martin, E., Rohr, S., Brigand, C., Duluc, I., Freund, J.-N., & Gross, I. (2022). CDX2 controls genes involved in the metabolism of 5-fluorouracil and is associated with reduced efficacy of chemotherapy in colorectal cancer. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 147, 112630.
Passet, M., Kim, R., Gachet, S., Sigaux, F., Chaumeil, J., Galland, A., Sexton, T., Quentin, S., Hernandez, L., Larcher, L., Bergugnat, H., Ye, T., Karasu, N., Caye-Eude, A., Heizmann, B., Duluc, I., Chevallier, P., Rousselot, P., Huguet, F., … Clappier, E. (2022). Concurrent CDX2 cis-deregulation and UBTF-ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL. Blood, blood.2021014723.
Sirakov, M., & Plateroti, M. (2022). Thyroid Hormone Signaling and Function: News from Classical and Emerging Models. Cells, 11(3), 453.